Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774
Malcomson L, Dalal G, Vass C, Wright S, Gray E, Trenaman L, Payne K, Renehan A. Introducing PrefCoRe: quantifying and implementing patient preferences for the treatment of high-risk rectal cancer, including the new strategy of organ preservation. Poster presented at the 2020 Association of Coloproctology (ACPGBI) Virtual Conference; July 2020. [abstract] Colorectal Dis. 2020 Jul; 22(S1):41-2.
Davis KL, Wei W, Meyers JL, Kilpatrick BS, Pandya N. Association between different hemoglobin a1c levels and clinical outcomes among elderly nursing home residents with type 2 diabetes mellitus. J Am Med Dir Assoc. 2014 Oct;15(10):757-962. doi: 10.1016/j.jamda.2014.06.007